<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Inmune Bio ( (INMB) ). On April 29, 2026, INmune Bio Inc. and its UK subsidiary INmune Bio International entered into an amended and restated material transfer and license agreement with UK charity Anthony Nolan, formalizing INmune Bio as a party and making it jointly liable for royalty obligations. The expanded deal secures long-term access to high-quality umbilical cord tissue for the CORDStrom™ mesenchymal stromal cell platform, which is designed to deliver standardized, off-the-shelf cell therapies across major global markets. Under the revised terms, Anthony Nolan grants INmune Bio an exclusive license to use and process donor materials and derivatives, in return for a 2% royalty on net product sales up to an annual £5 million cap and per-unit service fees that may be adjusted annually from 2027 based on UK inflation. The agreement, which can run up to 10 years from first commercial sale and includes flexible termination rights, adds stringent traceability, GMP and Human Tissue Authority quality requirements, bolstering INmune Bio’s manufacturing reliability as it advances CORDStrom™ programs in recessive dystrophic epidermolysis bullosa, oncology and inflammatory and degenerative diseases. The most recent analyst rating on (INMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page. Spark’s Take on INMB Stock According to Spark, TipRanks’ AI Analyst, INMB is a Neutral. INMB scores lower primarily due to weak financial performance (persistent losses and multi-year negative free cash flow) and limited valuation support (negative P/E, no dividend). This is partially offset by constructive earnings-call updates on regulatory/clinical momentum for CORDStrom and XPro, and a moderately positive technical setup that is tempered by longer-term downtrend signals and near-term overbought risk. To see Spark’s full report on INMB stock, click here. More about Inmune Bio INmune Bio Inc. is a clinical-stage biotechnology company listed on Nasdaq that develops therapies targeting the innate immune system to treat serious diseases. Its three main platforms are CORDStrom™, an allogeneic umbilical cord-derived mesenchymal stromal cell technology, XPro™, a dominant-negative TNF inhibitor for inflammatory conditions, and INKmune®, a cell-based therapy designed to enhance natural killer cell activity in cancer patients. The company focuses on leveraging these platforms to address high unmet medical needs across rare genetic disorders, oncology and chronic inflammatory and degenerative diseases. CORDStrom™ recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa, underscoring INmune Bio’s strategy of building a diversified pipeline across multiple indications under global regulatory frameworks in the U.S., UK and EU. Average Trading Volume: 408,174 Technical Sentiment Signal: Sell Current Market Cap: $39.35M See more data about INMB stock on TipRanks’ Stock Analysis page.</div>

INMB

LABU

SBIO

IBBQ

INmune Bio has expanded its license agreement with UK charity Anthony Nolan, securing long-term access to umbilical cord tissue for its CORDStrom™ platform. The revised deal includes a 2% royalty on net sales and stringent quality requirements. Analysts rate INMB stock as a Buy with a $7.00 price target, though Spark's AI Analyst considers it Neutral due to weak financial performance. INmune Bio focuses on therapies for serious diseases, leveraging its CORDStrom™, XPro™, and INKmune® platforms.

INmune Bio Expands Cord Tissue License for CORDStrom Platform